The effects of a nonpeptide, orally active mixed endothelin (ET) @entity11081 /ETB receptor antagonist, @entity61013 , and an @entity1811 ( @entity1811 ) inhibitor, @entity3372 , were evaluated after inter-renal aortic banding in the @entity35 . Separate sham, vehicle, and treatment groups were compared in each study. In vehicle-treated animals in the @entity3372 group, aortic banding for 4 weeks produced significant @entity1283 (247 +/- 5 mg/100 g bw vs. 305 +/- 11 mg/100 g bw; p < 0.001), right (upstream) @entity8 (380 +/- 6 mg/100 g bw vs. 559 +/- 28 mg/100 g bw; p < 0.001), and significant left (downstream) @entity8 (405 +/- 4 mg/100 g bw vs. 192 +/- 25 mg/100 g bw; p < 0.001). Continuous @entity3372 treatment (1 mg/kg p.o. once daily), begun 3 days before aortic banding, inhibited @entity1283 (305 +/- 11 mg/100 g bw vs. 266 +/- 7 mg/100 g bw; p < 0.05) but did not alter @entity8 or @entity194 . In a similarly designed study, @entity61013 (30 mg/kg p.o. b.i.d.) had no effect on the development of @entity1283 (298 +/- 7 mg/100 g bw vs. 310 +/- 12 mg/100 g bw) or @entity8 (561 +/- 15 mg/100 g bw vs. 575 +/- 19 mg/100 g bw), but abolished the development of @entity8 (158 +/- 16 mg/100 g bw vs. 395 +/- 19 mg/100 g bw; p < 0.001). [125I]ET-1 radioligand binding experiments indicated that the density of both @entity11081 and ETB receptors was increased dramatically (three- to fourfold) in the @entity8 compared to sham or @entity1184 kidneys. In situ hybridization studies indicate an upregulation of ETB receptor mRNA in the glomeruli of @entity8 within 5 days of aortic banding. In conclusion, an angiotensin-dependent mechanism may mediate @entity1283 associated with aortic banding, whereas ET-dependent mechanisms may mediate an @entity3202 response in the hypoperfused kidney, perhaps through an interaction with upregulated @entity11081 and/or ETB receptors.

Effects of endothelin receptor antagonism and XXXX inhibition on cardiac and renal remodeling in the @entity35 .

@entity3372 :: ('MESH:D017257', 'Chemical') :: ['ramipril'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal atrophy', 'atrophic kidneys', 'atrophic kidney cortex', 'renal hypertrophy'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic'] @entity1283 :: ('MESH:D006332', 'Disease') :: ['cardiac hypertrophy'] @entity11081 :: ('24326(Tax:10116)', 'Gene') :: ['ETA'] @entity3202 :: ('MESH:D016109', 'Disease') :: ['atrophic'] @entity61013 :: ('MESH:C098288', 'Chemical') :: ['SB 217242'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity1811 :: ('24310(Tax:10116)', 'Gene') :: ['ACE', 'angiotensin-converting enzyme']
@entity1811 :: (24310(Tax:10116),Gene) :: ['angiotensin-converting enzyme']
